Cytek Biosciences annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Cytek Biosciences Capital Expenditures (CapEx) Growth & History (CTKB)
Cytek Biosciences's capital expenditures (capex) was $4.1M for fiscal 2025.
View full Cytek Biosciences company overviewCytek Biosciences annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.1M | $559,000 | +15.86% |
| 2024 | 2024-12-31 | $3.5M | −$1.1M | −24.16% |
| 2023 | 2023-12-31 | $4.6M | −$5.1M | −52.32% |
| 2022 | 2022-12-31 | $9.7M | $5.4M | +123.37% |
| 2021 | 2021-12-31 | $4.4M | $2.8M | +182.09% |
| 2020 | 2020-12-31 | $1.5M | — | — |
Cytek Biosciences quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.2M | $639,000 | +40.52% |
| Q1 2026 | 2026-03-31 | $2.2M | $1.3M | +155.36% |
| Q4 2025 | 2025-12-31 | $1.0M | $107,000 | +11.97% |
| Q3 2025 | 2025-09-30 | $657,000 | −$354,000 | −35.01% |
| Q2 2025 | 2025-06-30 | $1.6M | $524,000 | +49.76% |
| Q1 2025 | 2025-03-31 | $849,000 | $282,000 | +49.74% |
| Q4 2024 | 2024-12-31 | $894,000 | −$606,000 | −40.40% |
| Q3 2024 | 2024-09-30 | $1.0M | −$319,000 | −23.98% |
| Q2 2024 | 2024-06-30 | $1.1M | −$260,000 | −19.80% |
| Q1 2024 | 2024-03-31 | $567,000 | $62,000 | +12.28% |
| Q4 2023 | 2023-12-31 | $1.5M | −$5.0M | −77.03% |
| Q3 2023 | 2023-09-30 | $1.3M | $220,000 | +19.82% |
| Q2 2023 | 2023-06-30 | $1.3M | −$15,000 | −1.13% |
| Q1 2023 | 2023-03-31 | $505,000 | −$275,000 | −35.26% |
| Q4 2022 | 2022-12-31 | $6.5M | $5.2M | +403.86% |
| Q3 2022 | 2022-09-30 | $1.1M | −$198,000 | −15.14% |
| Q2 2022 | 2022-06-30 | $1.3M | $77,000 | +6.16% |
| Q1 2022 | 2022-03-31 | $780,000 | $271,000 | +53.24% |
| Q4 2021 | 2021-12-31 | $1.3M | — | — |
| Q3 2021 | 2021-09-30 | $1.3M | $834,000 | +175.95% |
| Q2 2021 | 2021-06-30 | $1.3M | — | — |
| Q1 2021 | 2021-03-31 | $509,000 | — | — |
| Q3 2020 | 2020-09-30 | $474,000 | — | — |
Cytek Biosciences capital expenditures (capex) trends
Over the last five fiscal years, Cytek Biosciences's capital expenditures (capex) increased from $1.5M to $4.1M, a change of $2.5M. The latest reported quarter, Q2 2026, shows $2.2M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cytek Biosciences source filings ↗